(Total Views: 278)
Posted On: 08/02/2019 2:27:38 PM
Post# of 153929
Today interview .....
This is interesting in the study with colon cancer , I think different MOA they looking for..
--0:40..Results of NASH in about 6 weeks
study with colon cancer shows that Leronlimab inhibits angiogenesis , so may play a role with treatment of solid tumors
--1:50 stop tumors with high and low CCR5 expression.
--2:30 How Dr Pestell leaving may affect company - it will not...
Dr Cristofanilli is in charge ot TNBC treatment naive patients ,
and Dr Lolezari in charge of TNBC patients second and higher line , first patient is now tested.
HIV was not Dr Pestell research .
--4:30 , probably next week we will submit IND for colon cancer..
--5:45 financing
--6:10 with TO total about 15 mill doll , we cleared about 40 mill warrants,
we need about 10-15 mill doll more to the end of the year.
--6:40 we very close to some licensing , right to sell..
--
This is interesting in the study with colon cancer , I think different MOA they looking for..
--0:40..Results of NASH in about 6 weeks
study with colon cancer shows that Leronlimab inhibits angiogenesis , so may play a role with treatment of solid tumors
--1:50 stop tumors with high and low CCR5 expression.
--2:30 How Dr Pestell leaving may affect company - it will not...
Dr Cristofanilli is in charge ot TNBC treatment naive patients ,
and Dr Lolezari in charge of TNBC patients second and higher line , first patient is now tested.
HIV was not Dr Pestell research .
--4:30 , probably next week we will submit IND for colon cancer..
--5:45 financing
--6:10 with TO total about 15 mill doll , we cleared about 40 mill warrants,
we need about 10-15 mill doll more to the end of the year.
--6:40 we very close to some licensing , right to sell..
--
(3)
(0)
